You are here

Article metrics

Article menu

Download PDFPDF

Clinical/translational cancer immunotherapy
Original research
Risks and benefits of reinduction ipilimumab/nivolumab in melanoma patients previously treated with ipilimumab/nivolumab

 

Online download statistics by month:

Online download statistics by month: October 2021 to August 2025

AbstractFullPdf
Oct 202142042587
Nov 2021298299101
Dec 202116916938
Jan 202213113554
Feb 202213814258
Mar 202221922538
Apr 202223924345
May 202225025151
Jun 202225325358
Jul 202228829170
Aug 202233133634
Sep 202233934226
Oct 202227027827
Nov 202227327325
Dec 202223723920
Jan 202327127320
Feb 202331131221
Mar 202328528715
Apr 202320320329
May 202320220311
Jun 202323723920
Jul 202320920925
Aug 202321321424
Sep 202322522620
Oct 202319419520
Nov 202324024017
Dec 202319919932
Jan 2024515226
Feb 202413613622
Mar 202421121254
Apr 202414114442
May 2024949525
Jun 202412112417
Jul 202413713829
Aug 2024969523
Sep 2024555521
Oct 2024787824
Nov 2024909124
Dec 2024807722
Jan 2025979732
Feb 202524324430
Mar 202510210311
Apr 202511311424
May 2025575725
Jun 2025464622
Jul 2025110
Aug 2025110
Total859486611459